| 摘要: |
| ［摘要］ 乳腺癌是全球女性发病率较高的恶性肿瘤，其中人类表皮生长因子受体2（HER2）阳性乳腺癌病例占总乳腺癌病例的20%～30%。与其他分子分型的乳腺癌比，HER2阳性乳腺癌预后更差，更易复发和转移。近年来，HER2阳性乳腺癌治疗备受关注，针对抗HER2的靶向药物能显著改善HER2阳性乳腺癌患者的疗效。该文对HER2阳性乳腺癌靶向治疗的研究进展作一综述。 |
| 关键词: 乳腺癌 人类表皮生长因子受体2阳性 靶向治疗 分子机制 单克隆抗体 |
| DOI：10.3969/j.issn.1674-3806.2024.10.22 |
| 分类号:R 73 |
| 基金项目:江苏省高等教育教改研究项目（编号：2023JSJG292） |
|
| Research progress in targeted therapy for HER2-positive breast cancer |
|
WU You, DAI Jianguo
|
|
School of Medicine, Nanjing University of Chinese Medicine, Jiangsu 210023, China
|
| Abstract: |
| ［Abstract］ Breast cancer is a malignant tumor with a relatively high incidence in women worldwide. In breast cancer patients, human epidermal growth factor receptor 2(HER2)-positive breast cancer cases account for 20% to 30% of the total breast cancer cases, and compared with the other molecular types of breast cancer, HER2-positive breast cancer has a worse prognosis and is more prone to recurrence and metastasis. In recent years, the treatment of HER2-positive breast cancer has attracted much attention, the anti-HER2-targeted drugs can significantly improve the therapeutic effect of HER2-positive breast cancer patients. In this paper, the research progress in targeted therapy for HER2-positive breast cancer is reviewed. |
| Key words: Breast cancer Human epidermal growth factor receptor 2(HER2)-positive Targeted therapy Molecular mechanism Monoclonal antibody |
